The absorption and therapeutic effect of glucagon capsules are important aspects that need to be focused on during the research and development process. Due to the complexity of the gastrointestinal environment, the absorption efficiency of glucagon after oral administration may be affected by various factors, such as gastrointestinal pH, mucosal status, and patient breathing patterns. In order to improve the absorption and efficacy of glucagon capsule, researchers have conducted extensive experiments and optimization work. For example, by adjusting the types and proportions of excipients in the formulation, the physical properties of the pill can be improved, and its affinity with the gastrointestinal mucosa can be enhanced; By optimizing the shape and size of the pill, its retention time in the gastrointestinal tract can be reduced, and the release rate of the drug can be improved; By combining drugs or technologies that promote absorption, such as penetration enhancers and microneedling techniques, the absorption efficiency of glucagon can be further improved.
Our products From
 |
 |
 |
| Glucagon Powder | Glucagon Injection | Glucagon Pill |
 |
 |
| Glucagon Cream | Glucagon Capsule |
Glucagon COA
Glucagon on Fat Decomposition and Ketone Production: Fuel Conversion from Energy Storage to System Repair
Human energy metabolism is a finely regulated dynamic system that stores energy when there is excess and releases energy when there is a lack to sustain life activities. The core mechanism of this process involves the antagonistic effect of insulin and Glucagon Capsules: insulin dominates energy storage, while glucagon is responsible for energy release. When blood sugar levels drop, glucagon activates fat breakdown and ketone body production, converting stored fat into energy forms that can be utilized by key organs such as the brain and heart. This process not only involves the breakdown metabolism of adipose tissue, but also the conversion of energy forms through the synthesis of ketone bodies in the liver, ultimately forming a complete fuel supply chain from energy storage to system repair.
Glucagon: a molecular switch for energy release
The secretion regulation mechanism of glucagon
Glucagon is secreted by pancreatic alpha cells, and its secretion is regulated by three factors: blood glucose levels, neural regulation, and hormone feedback. When the blood glucose concentration is below 3.9mmol/L, the hypothalamic pituitary adrenal axis is activated, and sympathetic nervous system excitation directly stimulates alpha cells to secrete glucagon. At the same time, hypoglycemia inhibits the secretion of insulin by pancreatic beta cells, relieving the inhibitory effect on alpha cells and forming a dual regulatory mechanism. Under long-term starvation, the decrease in somatostatin secretion and the increase in free fatty acid levels further enhance the secretion of glucagon, forming a multi-level regulatory network.
Signal transduction of glucagon receptor
Glucagon binds to the G protein coupled receptor (GCGR) on the liver cell membrane, activating adenylate cyclase (AC) and increasing the intracellular concentration of adenosine monophosphate (cAMP). CAMP acts as a second messenger, activating protein kinase A (PKA) and subsequently phosphorylating key enzymes such as glycogen phosphorylase and hormone sensitive lipase (HSL). This signaling pathway not only promotes the breakdown of liver glycogen, but also initiates the process of fat breakdown through the activation of HSL, forming a synergistic regulation of glucose and lipid metabolism.
Antagonistic balance of energy metabolism
Glucagon and insulin form a yin-yang twin in energy metabolism. Insulin constructs energy reserves by promoting glucose uptake, glycogen synthesis, and fat storage; And glucagon establishes energy release channels by activating glycogen breakdown, gluconeogenesis, and lipolysis. This antagonistic effect forms a dynamic balance between postprandial and fasting states: postprandial insulin dominates energy storage, while fasting glucagon dominates energy release, ensuring that blood glucose concentrations are maintained within the physiological range of 3.9-6.1 mmol/L.
Fat breakdown: metabolic restructuring from storage to release
Glucagon Capsules activates HSL in adipocytes, catalyzing the hydrolysis of triglycerides (TG) into free fatty acids (FFA) and glycerol. This process is accompanied by the reduction of adipocyte volume and the release of FFA into the bloodstream. The activation of HSL requires PKA mediated phosphorylation of Ser563, Ser660, and Ser659 sites, with Ser563 phosphorylation being the key activation site. At the same time, glucagon inhibits the activity of acetyl CoA carboxylase (ACC), reduces fatty acid synthesis, and forms a bidirectional regulation of decomposition and synthesis.
Transport and utilization of free fatty acids
FFA released into the bloodstream binds with plasma albumin to form a transport complex, which is transported to tissues such as the liver, muscles, and heart. In the liver, FFA enters mitochondria through carnitine palmitoyltransferase-1 (CPT-1) and undergoes β - oxidation to produce acetyl CoA. This process produces a large amount of NADH and FADH2, which generate ATP through the electron transport chain to provide energy for the liver. Meanwhile, acetyl CoA serves as a substrate for ketone body synthesis, initiating the ketone body formation process.
Fat breakdown not only provides energy, but also regulates systemic metabolism through metabolic products. FFA can activate peroxisome proliferator activated receptor alpha (PPAR alpha), upregulate the expression of fatty acid oxidation related genes, and enhance the fatty acid utilization capacity of the liver and muscles. Glycerol is phosphorylated by glycerol kinase to glycerol-3-phosphate, which enters the gluconeogenesis pathway to generate glucose, forming a cross regulation of fat sugar metabolism. In addition, adenosine monophosphate activated protein kinase (AMPK) produced by fat breakdown can inhibit the mTOR signaling pathway, reduce protein synthesis, and lower energy expenditure.
Ketone Formation: Revolutionary Conversion of Energy Forms
Biochemical pathways for ketone synthesis
Ketone body formation mainly occurs in liver mitochondria, using acetyl CoA as a substrate and undergoing three enzymatic reactions: firstly, two molecules of acetyl CoA are catalyzed by acetyl CoA thiolase (ACAT) to form acetyl CoA; secondly, acetyl CoA and another molecule of acetyl CoA are catalyzed by 3-hydroxy-3-methylglutaryl-CoA synthase (HMG CoA synthase) to form HMG CoA; Finally, HMG CoA is cleaved into acetoacetic acid and acetyl CoA by HMG CoA lyase (HMGCL). Acetoacetic acid can spontaneously decarboxylate to produce acetone, or be reduced to β - hydroxybutyric acid (BHB) under the catalysis of acetoacetate thiokinase (AKR1C3).
Regulatory mechanism of ketone body formation
Ketone production is regulated by both glucagon and insulin. Glucagon Capsules activates PKA, phosphorylates and activates CPT-1, promoting fatty acid entry into mitochondria and increasing acetyl CoA supply, thereby upregulating ketone body production. At the same time, glucagon inhibits the activity of pyruvate carboxylase (PC), reduces the consumption of acetyl CoA by gluconeogenesis, and further promotes ketone body synthesis. Insulin activates protein phosphatase 2A (PP2A) to dephosphorylate and inactivate CPT-1, inhibiting fatty acid oxidation and ketone body formation. This bidirectional regulation ensures that ketone body production is enhanced on an empty stomach or in a state of hunger, and inhibited after eating.
Transport and Utilization of Ketones
Ketones enter the bloodstream through simple diffusion, with BHB and acetoacetic acid being the main modes of transport. In tissues such as the heart, brain, and skeletal muscle, BHB enters cells through monocarboxylate transporters (MCT1/2) and is converted to acetoacetate by β - hydroxybutyrate dehydrogenase (BDH1) catalysis. Acetylacetic acid reacts with succinyl CoA catalyzed by succinyl CoA thiotransferase (SCOT) to form acetyl CoA, which ultimately enters the tricarboxylic acid cycle (TCA) for complete oxidation. This process provides alternative energy for glucose dependent organs such as the brain, especially during long-term hunger or low carbohydrate diets, ketone bodies can provide 60% -70% of the energy needed by the brain.
System Repair: From Energy Supply to Organizational Protection
Ketones not only provide energy to the brain, but also have a direct neuroprotective effect. BHB can promote neuronal survival and synaptic plasticity by inhibiting histone deacetylases (HDACs), upregulating the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). In addition, BHB can activate the Nrf2 signaling pathway, upregulate antioxidant enzyme expression, and reduce oxidative stress damage. In the Alzheimer's disease model, a ketone body diet can reduce β - amyloid deposition, improve cognitive function, and suggest the potential therapeutic value of ketone bodies in neurodegenerative diseases.
Anti inflammatory effects of ketones
Ketones can inhibit NLRP3 inflammasome activation and reduce the release of pro-inflammatory cytokines such as IL-1 β and IL-18. BHB can competitively bind to G protein coupled receptor GPR109A, inhibit macrophage activation, and reduce inflammatory response. In the ischemia-reperfusion injury model, ketone body pretreatment can reduce myocardial infarction area and improve cardiac function, which is related to the inhibition of inflammatory response and oxidative stress. In addition, ketone bodies can increase the abundance of short chain fatty acid (SCFA) producing bacteria by regulating the composition of gut microbiota, further enhancing anti-inflammatory effects.
Long term exposure to ketones can induce cellular metabolic reprogramming, enhance antioxidant capacity, and improve energy metabolism efficiency. In the liver, ketone bodies can activate the AMPK signaling pathway, upregulate the expression of fatty acid oxidation related genes, reduce lipid deposition, and prevent non-alcoholic fatty liver disease (NAFLD). In muscles, ketone bodies can inhibit the proteasome pathway and autophagy lysosome pathway, reduce protein degradation, and maintain muscle mass. In addition, ketone bodies can regulate mitochondrial dynamics, promote mitochondrial fusion, enhance mitochondrial function, and improve cellular stress tolerance.
Frequently Asked Questions
Why is it difficult to achieve oral glucagon for a long time, and what are the core technological barriers faced by the tablets?
+
-
Glucagon is a protein that is immediately degraded by stomach acid and intestinal digestive enzymes after oral administration, losing its activity. The core technological barrier lies in how to design the carrier to pass through the entire digestive tract and enter the bloodstream unscathed.
What is the new therapeutic scenario targeted by oral preparations, which is different from the positioning of "raising blood sugar" in emergency injections?
+
-
It is mainly aimed at preventive treatment, such as taking it before high-intensity exercise or a meal rich in fat for diabetes patients to "predict in advance" the body to avoid possible post exercise or post meal hypoglycemia, which is a concept change from "fire fighting" to "fire prevention".
What disruptive technological approach is currently used in leading oral glucagon preparations, such as Dasiglucagon?
+
-
Adopting liquid filled hard capsule technology, the core is composed of a special ion exchange polymer. This polymer can act like a 'bodyguard', binding to drugs in the stomach acid environment and protecting them until they enter the more acidic gut before being safely released.
Hot Tags: glucagon capsules, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale